FDA Launches New REMS Website
The agency streamlines risk and mitigation information.
FDA has launched its new Risk Evaluation and Mitigation Strategies (REMS) website. REMS controls were created as part of the Food and Drug Administration Amendments Act (FDAAA) of 2007, which gave FDA the authority to require REMS from manufacturers so the agency could ensure that the benefits of a drug product outweigh the potential risks. A REMS creates a strategy for managing serious risks associated with a drug. FDA may require a REMS for approval of a new drug or when there is new safety information on an already approved drug.
The new website has streamlined REMS information into one easy-to-use table that includes currently approved and shares-system REMS, instead of the multiple tables and databases previously found on FDA’s website. The searchable table includes the medication guide, communication plan, ETASU (Elements to Assure Safe Use), and implementation system for each drug or biologic. Historical and released REMS can be downloaded from the website.
Source: FDA
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
